Ocular Therapeutix, Inc. (OCUL) is a publicly traded Healthcare sector company. As of May 21, 2026, OCUL trades at $8.04 with a market cap of $1.83B and a P/E ratio of -5.63. OCUL moved +0.38% today. Year to date, OCUL is -30.48%; over the trailing twelve months it is +5.66%. Its 52-week range spans $5.79 to $16.44. Analyst consensus is strong buy with an average price target of $24.50. Rallies surfaces OCUL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes OCUL SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $8.04 |
| Market Cap | $1.83B |
| P/E Ratio | -5.63 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.44 |
| 52-Week Low | $5.79 |
| Volume | 6.69K |
| Avg Volume | 0 |
| Revenue (TTM) | $52.04M |
| Net Income | $-290.50M |
| Gross Margin | 87.24% |
9 analysts cover OCUL: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.50.